Phenotype frequencies for HLA-DR in primary progressive multiple sclerosis, relapsing-remitting/secondary progressive multiple sclerosis, and controls
| Serological group | PP-MS | RR/SP-MS | Controls | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Refs 5 and 21 (n = 187) | Current (n = 50) | Total (n = 237) | Refs 5 and 21 (n = 929) | Current (n = 71) | Total (n = 1000) | Refs 5 and 21 (n = 853) | Current (n = 109) | Total (n = 962) | |
| Pooled data from two previous studies that have tested well defined PP-MS patients5,21 are compared with data from the current study. | |||||||||
| MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting; SP, secondary progressive. | |||||||||
| 01 | 38 (20.3%) | 10 (20%) | 48 (20.3%) | 137 (14.7%) | 9 (12.7%) | 146 (14.6%) | 181 (21.2%) | 25 (22.9%) | 206 (21.4%) |
| 02 | 116 (62.0%) | 31 (62%) | 150 (63.3%) | 591 (63.6%) | 50 (70.4%) | 641 (64.1%) | 277 (32.5%) | 34 (31.2%) | 311 (32.3%) |
| 03 | 49 (26.2%) | 14 (28%) | 63 (26.6%) | 218 (23.5%) | 21 (29.6%) | 239 (23.9%) | 221 (25.9%) | 29 (26.6%) | 250 (26.0%) |
| 04 | 59 (31.6%) | 14 (28%) | 73 (30.8%) | 244 (26.3%) | 18 (25.4%) | 262 (26.2%) | 305 (35.7%) | 41 (37.6%) | 346 (36.0%) |
| 05 | 11 (5.9%) | 4 (8%) | 15 (6.3%) | 106 (11.4%) | 8 (11.3%) | 114 (11.4%) | 120 (14.1%) | 24 (22.0%) | 144 (15.0%) |
| 06 | 37 (19.8%) | 12 (24%) | 49 (20.7%) | 184 (19.8%) | 11 (15.5%) | 195 (19.5%) | 232 (27.2%) | 23 (21.1%) | 255 (26.5%) |
| 07 | 20 (10.7%) | 8 (16%) | 28 (11.8%) | 95 (10.2%) | 11 (15.5%) | 106 (10.6%) | 167 (19.6%) | 19 (17.4%) | 186 (19.3%) |
| 08 | 9 (4.8%) | 2 (4%) | 11 (4.6%) | 79 (8.5%) | 5 (7.0%) | 84 (8.4%) | 57 (6.7%) | 6 (5.5%) | 63 (6.5%) |
| 09 | 4 (2.1%) | 1 (2%) | 5 (2.1%) | 7 (0.8%) | 0 (0%) | 7 (0.7%) | 24 (2.8%) | 3 (2.8%) | 27 (2.8%) |
| 10 | 4 (2.1%) | 0 (0%) | 4 (1.7%) | 11 (1.2%) | 0 (0%) | 11 (1.1%) | 12 (1.4%) | 3 (2.8%) | 15 (1.6%) |